Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations.
Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A. Li X, et al. Among authors: pilie pg. Cancer Discov. 2022 Jun 2;12(6):1542-1559. doi: 10.1158/2159-8290.CD-21-0832. Cancer Discov. 2022. PMID: 35412613 Free PMC article.
Precision Medicine: Progress, Pitfalls, and Promises.
Pilié PG, LoRusso PM, Yap TA. Pilié PG, et al. Mol Cancer Ther. 2017 Dec;16(12):2641-2644. doi: 10.1158/1535-7163.MCT-17-0904. Mol Cancer Ther. 2017. PMID: 29203693 No abstract available.
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.
Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. Pilié PG, et al. Clin Cancer Res. 2019 Jul 1;25(13):3759-3771. doi: 10.1158/1078-0432.CCR-18-0968. Epub 2019 Feb 13. Clin Cancer Res. 2019. PMID: 30760478 Review.
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.
Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Garmezy B, et al. Among authors: pilie pg. JCO Precis Oncol. 2022 Feb;6:e2100267. doi: 10.1200/PO.21.00267. JCO Precis Oncol. 2022. PMID: 35108036 Free PMC article.
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilié PG, Thompson TC. Geng C, et al. Among authors: pilie pg. Clin Cancer Res. 2023 Nov 1;29(21):4464-4478. doi: 10.1158/1078-0432.CCR-23-1439. Clin Cancer Res. 2023. PMID: 37581614 Free PMC article.
Targeting ATR in patients with cancer.
Ngoi NYL, Pilié PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Ngoi NYL, et al. Among authors: pilie pg. Nat Rev Clin Oncol. 2024 Apr;21(4):278-293. doi: 10.1038/s41571-024-00863-5. Epub 2024 Feb 20. Nat Rev Clin Oncol. 2024. PMID: 38378898 Review.
46 results